El interés en corto de VSee Health da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de VSee Health. Los datos de interés en corto se actualizan cada dos semanas.

VSee Health (NASDAQ:VSEE) Bolsa, Informe de interés en corto

VSee Health

VSee Health Inc is a telehealth software platform. VSee's telemedicine solution, offering a fast, secure text + video collaboration app HIPAA messenger, and fully customizable virtual waiting rooms and clinics, is a complete telehealth platform that fits into any workflow. The VSee proprietary technology platform and modular software solution enable users to plug and play telehealth services with end-to-end encrypted video streaming integrated with patient metrics, electronic medical records, and other sensitive data, with multiple other interactive functionalities. The company's products include VSee Clinic, VSee Messenger, VSee APIs, VSee Remote patient monitoring, VSee Telehealth Staffing.

VSee Health Inc

D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) with a Buy and maintains $10 price target.

News

Price Target

Analyst Ratings

CRVO

D. Boral Capital Maintains Buy on CervoMed, Maintains $10 Price Target

Guidance

SKYX

SKYX Platforms Sees Prelim. Q4 Revenue $23.7M Vs $24.3M Est.

Citizens Capital Markets analyst Aaron Hecht reiterates Chicago Atlantic Real (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) with a Market Outperform and maintains $20 price target.

Reiteration

REFI

Citizens Capital Markets Reiterates Market Outperform on Chicago Atlantic Real, Maintains $20 Price Target

On Monday, Incyte&nbsp;Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>)&nbsp;released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">hidradenitis suppurativa (HS)</a>.
Hidradenitis suppurativa (HS), also known as acne inversa, is&nbsp;a chronic inflammatory skin condition characterized by painful, recurrent boil-like lumps, often in areas where skin rubs together like the armpits and groin, that can lead to abscesses and scarring.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44245346/eli-lilly-incyte-partnered-fda-approved-drug-shows-encouraging-efficacy-in-adolescent-patients-with-patchy-hair-loss" rel="noreferrer noopener">Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss</a>
STOP-HS1 and STOP-HS2 studies met their primary endpoint at both tested doses (45 mg and 75 mg).
A significantly higher proportion of patients treated with povorcitinib once daily versus placebo achieved Hidradenitis Suppurativa Clinical Response (HiSCR), a ≥50% reduction from baseline in the total abscess and inflammatory nodule count (AN count), with no increase from baseline in abscess or <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44352766/incyte-announces-positive-topline-results-from-two-phase-3-clinical-trials-of-povorcitinib-in-pati" rel="noreferrer noopener">draining tunnel count</a>.
The percentage of povorcitinib treated patients achieving HiSCR50 compared to placebo at Week 12 was:
<ul>
<li>STOP-HS1: 45 mg: 40.2% vs. 29.7% [P=0.024]; 75 mg: 40.6% vs 29.7% [P=0.022].</li>
<li>STOP-HS2: 45 mg: 42.3% vs. 28.6% [P=0.004]; 75 mg: 42.3% vs. 28.6% [P=0.003].</li>
</ul>
Within a predefined subgroup of patients previously exposed to biologics, povorcitinib demonstrated greater differential efficacy (HiSCR50) when compared to placebo:
<ul>
<li>STOP-HS1: 45 mg: 34.2% vs. 21.9% [P=0.096]; 75 mg: 37.8% vs. 21.9% [P=0.037].</li>
<li>STOP-HS2: 45 mg: 45.0% vs. 19.5% [P=0.001]; 75 mg: 40.0% vs. 19.5% [P=0.005].</li>
</ul>
In addition, at Week 12, patients treated with povorcitinib achieved deep levels of clinical response with a greater proportion achieving HiSCR75, reduction in flares,&nbsp;&gt;3-point decrease in the Skin Pain Numeric Rating Scale (NRS) score and Skin Pain NRS30.
Furthermore, povorcitinib demonstrated rapid onset of response, including rapid skin pain reduction.
The overall safety profile of povorcitinib is consistent with previous data. No new safety signals were observed and both doses were well tolerated.
Last week, Incyte revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura) in adult patients with prurigo nodularis, a chronic skin condition characterized by <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44229321/incyte-releases-mixed-data-from-late-stage-opzelura-studies-in-skin-disease-characterized-by-itchy-firm-lumps" rel="noreferrer noopener">very itchy firm lumps</a>.
Price Action: INCY stock is down 11.90% at $59.78 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44355022/science-applications-q4-earnings-crush-estimates-helped-by-new-contract-volume" target="_blank" rel="noreferrer noopener">Science Applications Q4 Earnings Crush Estimates Helped By New Contract Volume, Stock Gains</a></li>
</ul>

Biotech

Large Cap

Health Care

Movers

Trading Ideas

General

INCY

Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls

Citizens Capital Markets analyst Trevor Walsh reiterates Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) with a Market Outperform and maintains $180 price target.

Citizens Capital Markets Reiterates Market Outperform on Cloudflare, Maintains $180 Price Target

Citizens Capital Markets analyst Aaron Hecht reiterates Innovative Ind Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) from Market Perform to Market Perform.

IIPR

Citizens Capital Markets Reiterates Market Perform on Innovative Ind Propsto Market Perform

VCSA

Vacasa Accepts Casago's Revised Acquisition Proposal To Increase Price To $5.30/Share

Citizens Capital Markets analyst Brian McKenna reiterates FTAI Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIP#NASDAQ">FIP</a>) from Market Outperform to Market Outperform.

Citizens Capital Markets Reiterates Market Outperform on FTAI Infrastructureto Market Outperform

Financial giants have made a conspicuous bullish move on Apple. Our analysis of options history for Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) revealed 15 unusual trades.
Delving into the details, we found 46% of traders were bullish, while 40% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $213,179, and 9 were calls, valued at $406,820.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $200.0 to $230.0 for Apple over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Apple's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Apple's substantial trades, within a strike price spectrum from $200.0 to $230.0 over the preceding 30 days.
<h3>Apple 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742219174_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.05</td>
<td>$3.0</td>
<td>$3.03</td>
<td>$215.00</td>
<td>$135.3K</td>
<td>8.8K</td>
<td>3.1K</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.45</td>
<td>$3.35</td>
<td>$3.4</td>
<td>$215.00</td>
<td>$56.1K</td>
<td>8.8K</td>
<td>4.8K</td>
</tr>
<tr>
<td>AAPL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/11/25</td>
<td>$2.24</td>
<td>$2.24</td>
<td>$2.24</td>
<td>$200.00</td>
<td>$46.8K</td>
<td>1.5K</td>
<td>3.4K</td>
</tr>
<tr>
<td>AAPL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$20.35</td>
<td>$17.1</td>
<td>$17.7</td>
<td>$230.00</td>
<td>$46.0K</td>
<td>16.2K</td>
<td>26</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.15</td>
<td>$215.00</td>
<td>$39.0K</td>
<td>8.8K</td>
<td>3.1K</td>
</tr>
</tbody>
</table>

<h3>About Apple</h3>
Apple is among the largest companies in the world, with a broad portfolio of hardware and software products targeted at consumers and businesses. Apple's iPhone makes up a majority of the firm sales, and Apple's other products like Mac, iPad, and Watch are designed around the iPhone as the focal point of an expansive software ecosystem. Apple has progressively worked to add new applications, like streaming video, subscription bundles, and augmented reality. The firm designs its own software and semiconductors while working with subcontractors like Foxconn and TSMC to build its products and chips. Slightly less than half of Apple's sales come directly through its flagship stores, with a majority of sales coming indirectly through partnerships and distribution.
<h3>Current Position of Apple</h3>
<ul>
<li>With a trading volume of 2,107,941, the price of AAPL is down by -0.53%, reaching $212.35.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 45 days from now.</li>
</ul>
<h3>Expert Opinions on Apple</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $300.67.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Wedbush lowers its rating to Outperform with a new price target of $325. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Apple, maintaining a target price of $252. 
&#x2A; In a cautious move, an analyst from Wedbush downgraded its rating to Outperform, setting a price target of $325. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Apple with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

AAPL

Spotlight on Apple: Analyzing the Surge in Options Activity

Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) revealed 17 unusual trades.
Delving into the details, we found 52% of traders were bullish, while 41% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $374,400, and 15 were calls, valued at $1,043,500.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $660.0 to $1240.0 for Eli Lilly over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Eli Lilly's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Eli Lilly's significant trades, within a strike price range of $660.0 to $1240.0, over the past month.
<h3>Eli Lilly Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742219169_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$89.0</td>
<td>$89.0</td>
<td>$89.0</td>
<td>$880.00</td>
<td>$267.0K</td>
<td>1.2K</td>
<td align="right">44</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$150.3</td>
<td>$148.0</td>
<td>$148.0</td>
<td>$720.00</td>
<td>$222.1K</td>
<td>13</td>
<td align="right">7</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$74.0</td>
<td>$71.8</td>
<td>$74.0</td>
<td>$800.00</td>
<td>$148.0K</td>
<td>673</td>
<td align="right">21</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$150.3</td>
<td>$148.35</td>
<td>$148.35</td>
<td>$720.00</td>
<td>$118.6K</td>
<td>13</td>
<td align="right">30</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$89.5</td>
<td>$89.5</td>
<td>$89.5</td>
<td>$880.00</td>
<td>$107.4K</td>
<td>1.2K</td>
<td align="right">13</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Eli Lilly's Current Market Status</h3>
<ul>
<li>With a trading volume of 116,120, the price of LLY is up by 0.48%, reaching $817.36.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 45 days from now.</li>
</ul>
<h3>Expert Opinions on Eli Lilly</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $1100.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Eli Lilly, maintaining a target price of $1100. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

This Is What Whales Are Betting On Eli Lilly

Whales with a lot of money to spend have taken a noticeably bullish stance on Costco Wholesale.
Looking at options history for Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) we detected 13 trades.
If we consider the specifics of each trade, it is accurate to state that 38% of the investors opened trades with bullish expectations and 30% with bearish.
From the overall spotted trades, 10 are puts, for a total amount of $952,029 and 3, calls, for a total amount of $143,070.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $780.0 to $1140.0 for Costco Wholesale over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Costco Wholesale's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Costco Wholesale's substantial trades, within a strike price spectrum from $780.0 to $1140.0 over the preceding 30 days.
<h3>Costco Wholesale 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742219163_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>COST</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$240.45</td>
<td>$234.15</td>
<td>$237.3</td>
<td>$1140.00</td>
<td>$593.2K</td>
<td align="right">37</td>
<td align="right">25</td>
</tr>
<tr>
<td>COST</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$31.0</td>
<td>$29.0</td>
<td>$30.05</td>
<td>$780.00</td>
<td>$72.1K</td>
<td align="right">157</td>
<td align="right">24</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$27.65</td>
<td>$24.65</td>
<td>$24.7</td>
<td>$880.00</td>
<td>$66.6K</td>
<td align="right">141</td>
<td align="right">27</td>
</tr>
<tr>
<td>COST</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$83.0</td>
<td>$79.25</td>
<td>$83.0</td>
<td>$985.00</td>
<td>$66.4K</td>
<td align="right">21</td>
<td align="right">8</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$228.0</td>
<td>$219.0</td>
<td>$224.4</td>
<td>$780.00</td>
<td>$44.8K</td>
<td align="right">11</td>
<td align="right">2</td>
</tr>
</tbody>
</table>

<h3>About Costco Wholesale</h3>
Costco operates a membership-based, no-frills retail model, predicated on offering a select product assortment in bulk quantities at bargain prices. The firm avoids maintaining costly product displays by keeping inventory on pallets and limits distribution expenses by storing its inventory at point of sale in the warehouse. Given Costco's frugal cost structure, the firm is able to price its merchandise below competing retailers, driving high sales volume per warehouse and allowing the retailer to generate strong profits on thin margins. Costco operates over 600 warehouses in the United States and boasts over 60% market share in the domestic warehouse club industry. Internationally, Costco operates another 280 warehouses, primarily in markets such as Canada, Mexico, Japan, and the UK.
After a thorough review of the options trading surrounding Costco Wholesale, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Costco Wholesale</h3>
<ul>
<li>Currently trading with a volume of 77,768, the COST's price is down by -0.1%, now at $903.05. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 73 days.</li>
</ul>
<h3>Expert Opinions on Costco Wholesale</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $1075.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Costco Wholesale, targeting a price of $980. 
&#x2A; An analyst from Telsey Advisory Group has decided to maintain their Outperform rating on Costco Wholesale, which currently sits at a price target of $1100. 
&#x2A; Maintaining their stance, an analyst from Telsey Advisory Group continues to hold a Outperform rating for Costco Wholesale, targeting a price of $1100. 
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Outperform rating for Costco Wholesale, targeting a price of $1125. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Costco Wholesale with a target price of $1070. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Costco Wholesale with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

COST

Unpacking the Latest Options Trading Trends in Costco Wholesale

As Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)&nbsp; investors grow uneasy about his divided focus, Elon Musk&#8217;s past statements are resurfacing—including his claim that he never wanted to be CEO because it &#8220;hurts&#8221; his heart.
<h2 class="wp-block-heading">Investors Question Musk&#8217;s Priorities</h2>
Tesla&#8217;s stock has plummeted 52% from its mid-December high, with shares declining every week since Musk went to Washington, D.C. Investors worry that <a href="https://www.benzinga.com/markets/25/03/44242181/elon-musk-admits-juggling-between-tesla-doge-is-difficult-says-running-businesses-with-great-difficulty-as-tsla-stock-plunges-50-in-3-months">Musk is spread too thin</a>, juggling Tesla alongside SpaceX, X, xAI, The Boring Company, Neuralink and now his role in Washington, overseeing government cost-cutting efforts.
&#8220;It&#8217;s become clear he&#8217;s now spending more time on DOGE than anything else,&#8221; Garrett Nelson, a senior equity analyst at CFRA Research, <a href="https://www.businessinsider.com/tesla-stock-price-crash-investors-want-elon-musk-ceo-tsla-2025-3">told</a> Business Insider, referencing <a href="https://www.benzinga.com/markets/25/02/43972234/trump-and-elon-musks-cost-cutting-measures-fail-to-curb-rising-us-government-spending-report">Musk&#8217;s commitments</a> at the Department of Government Efficiency.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/qnetic-2">This 12,000 RPM Spinning Battery With Over $100 Million In LOIs Could Be The Missing Link For Green Energy — Here&#8217;s Why Early Investors Are Flocking To Invest Before Funding Closes</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
Retail investors have voiced their frustration as well. A StockTwits <a href="https://stocktwits.com/StocktwitsPolls/message/606655619">poll</a> found that 60% of respondents believe Musk's political focus is hurting Tesla, while only 25% dismissed the concern as media hype.
<h2 class="wp-block-heading">Musk&#8217;s Reluctance to Be CEO</h2>
Musk has stated multiple times that he <a href="https://www.benzinga.com/general/24/01/36574844/elon-musk-says-he-never-wanted-to-be-ceo-of-tesla-or-anything-running-companies-hurts-my-heart-but-h">never aspired to be Tesla's CEO</a>. In a 2020 <a href="https://www.youtube.com/watch?v=NxmO_QuD4Do">interview</a>, he clarified, &#8220;This is misinterpreted like I somehow don't love Tesla, which I do, it's just like trying not to go insane with work.&#8221;
His reluctance dates back to his early career. At Zip2, his first major startup, he was blocked from taking the CEO role. At X.com, which after a merger became PayPal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>), he was pushed out of leadership over concerns about his executive experience. When Tesla was founded in 2003, Musk initially took a backseat, investing heavily but not stepping in as CEO until 2008, when the company faced financial turmoil.
Trending: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a>
In June 2022, Musk reiterated his hesitation, <a href="https://x.com/elonmusk/status/1532265043391291392">posting</a> on the former Twitter: &#8220;I never wanted to be CEO—just wanted to work on product/technology.&#8221; He followed up with another telling remark: &#8220;Running companies hurts my heart, but I don't see any other way to bring technology &amp; design to fruition.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I never wanted to be CEO – just wanted to work on product/technology. Bill Harris sounded like he would be a great CEO, given his Intuit experience, but he was not. Running companies hurts my heart, but I don't see any other way to bring technology &amp; design to fruition.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1532265043391291392?ref_src=twsrc%5Etfw">June 2, 2022</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h2 class="wp-block-heading">Calls for Musk to Step Back</h2>
With Tesla facing <a href="https://www.benzinga.com/news/25/03/44209579/unprecedented-slide-tesla-sales-plummet-45-in-europe-as-musks-net-worth-dives-5-2b-in-a-week">slowing vehicle sales</a> in key markets like Europe and China, some analysts believe Musk should finally step away from daily operations.
But these calls aren&#8217;t anything new. In February 2024, Will McDonough, CEO of Corestone Capital, <a href="https://fortune.com/2024/02/03/elon-musk-tesla-ceo-board-directors-corporate-governance/">told</a> Fortune, &#8220;When you have a founder at the helm, it's both a gift and a curse because visionaries rarely make great CEOs.&#8221; He suggested Tesla find a professional manager, much like Google brought in Eric Schmidt to oversee operations while the founders focused on innovation. Or just like Elon did when he brought in Linda Yaccarino as the <a href="https://www.benzinga.com/news/24/07/39660279/linda-yaccarino-feels-the-heat-as-elon-musk-builds-pressure-amid-xs-plummeting-ad-revenue-report">CEO of X</a>.
Others have pointed to Zack Kirkhorn, Tesla's former finance chief, as someone who could have taken on a larger role, but he abruptly left the company in August with no explanation. Gwynne Shotwell, SpaceX's president, has also been cited as one of the few executives who have worked seamlessly with Musk over a long period.
See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it">Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</a>
<h2 class="wp-block-heading">The Catch-22 for Tesla Investors</h2>
Despite the growing concerns, analysts say Musk remains essential to Tesla&#8217;s stock price. Ross Gerber, a <a href="https://www.benzinga.com/25/03/44321998/why-ross-gerber-finds-tesla-stock-expensive-despite-its-50-plunge-fundamental-story-has-to-be-revalued">longtime Tesla investor</a>, estimated that &#8220;about $150 to $200 per share&#8221; of Tesla's value is based on Musk's involvement. At the same time, his controversial statements and governance decisions—such as his <a href="https://www.benzinga.com/news/24/01/36652560/elon-musk-wants-to-own-25-of-tesla-heres-how-much-of-the-ev-stock-the-ceo-owns">demand for 25% control</a> of Tesla's AI efforts—have fueled criticism.
Randall Peterson, a professor at the London Business School, believes the best solution is for Musk to take a backseat. &#8220;Could they find some kind of accommodation that keeps Elon in the atmosphere but takes him out of day-to-day management? If they can come to that, then they're in business. If not, it's a huge risk,&#8221; he told Fortune.
Even Musk himself has floated the idea of stepping down. Tesla director James Murdoch testified in a trial over Musk&#8217;s 2018 Tesla pay package that a successor had been identified.&nbsp;
Read Next:
<ul>
<li>This platform is reshaping how you invest in private companies —<a href="https://www.benzinga.com/money/kingscrowd-adv"> and you can be a part of it for $0.18 per share</a></li>
<li><a href="https://www.benzinga.com/money/startengine-own">The $1.3 Billion Startup Investment Boom: How This Company's Explosive Growth Is Opening Doors For Everyday Investors With A New $500 Minimum</a></li>
</ul>

PYPL

TSLA

With Doubts Over Musk's Tesla Commitment Growing, His Own Words Resurface—He Once Said He Never Wanted To Be CEO As It 'Hurts' His Heart

Earnings

Lytus Technologies H1 2025 Revenue Growth $12.01M Up From $9.66M YoY

Rosenblatt analyst Kevin Cassidy maintains Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) with a Buy and maintains $8 price target.

Rosenblatt Maintains Buy on Canaan, Maintains $8 Price Target

Citizens Capital Markets analyst Aaron Hecht reiterates Advanced Flower Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFCG#NASDAQ">AFCG</a>) from Market Perform to Market Perform.

AFCG

Citizens Capital Markets Reiterates Market Perform on Advanced Flower Capitalto Market Perform

GLMD

Galmed Pharmaceuticals Shares Resumed Trade

Rosenblatt analyst Barton Crockett maintains Emerald Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EEX#NYSE">EEX</a>) with a Buy and maintains $7.8 price target.

Rosenblatt Maintains Buy on Emerald Holding, Maintains $7.8 Price Target

On Monday, Microchip Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) introduced a fresh offering for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44353847/microchip-introduces-electric-two-wheeler-ecosystem-to-accelerate-e-mobility-innovation" rel="noreferrer noopener">the electric two-wheeler (E2W) industry</a>, designed to ease the development of e-scooters and e-bikes.
Microchip&#8217;s E2W ecosystem aims to tackle key issues like power efficiency, system integration, and safety. These solutions provide manufacturers with a high-quality, scalable platform to develop dependable, feature-packed electric two-wheelers with faster market entry.
The ecosystem&#8217;s key solutions to optimize electric two-wheeler performance include advanced battery management systems (BMS), which improve power utilization and extend battery life.
&#8220;Manufacturers often struggle with optimizing power efficiency, ensuring seamless system integration and meeting evolving safety standards,&#8221; said corporate vice president of Microchip&#8217;s dsPIC business unit, Joe Thomsen.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44327146/whats-going-on-with-palantir-technologies-stock-today" rel="noreferrer noopener">Palantir Technologies Partners With RCM Company R1For AI Lab&nbsp;</a>
&#8220;Microchip&#8217;s Electric Two-Wheeler Ecosystem directly addresses these design challenges with pre-validated, high-performance solutions that help accelerate product development and enhance vehicle reliability.&#8221;
The 48V to 12V power conversion system enhances system efficiency, while the 7.4 kW single-phase AC EV charger supports fast and flexible home charging.
Additionally, the modular design of the ecosystem ensures smooth development of various power levels and feature sets for e-scooters and e-bikes.
The Vehicle Control Unit (VCU), along with technologies like remote keyless entry and hands-on/off detection, enhances security.
The integrated telematics and asset tracking support real-time monitoring and theft prevention, aiding in better fleet management. Cloud-enabled diagnostic tools provide remote performance tracking, benefiting both riders and fleet operators.
Price Action: MCHP shares traded higher by 1.64% at $54.38 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44352234/astrazeneca-seals-deal-for-esobiotec-to-advance-cell-therapy-details" target="_blank" rel="noreferrer noopener">AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details</a></li>
</ul>
Photo via Shutterstock.

Equities

MCHP

Microchip Launches E2W Ecosystem To Boost Efficiency And Safety In Electric Scooters

<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="500" height="280" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/17085357/Hello-Group-0317.jpeg" alt="" class="wp-image-8023" style="width:920px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/17085357/Hello-Group-0317.jpeg 500w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/17085357/Hello-Group-0317-300x168.jpeg 300w" sizes="(max-width: 500px) 100vw, 500px" /></figure>
The operator of the Momo dating app said revenue from its global business could potentially double to 2 billion yuan this year
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>Hello Group's revenue fell 12% in the fourth quarter, while its net income plunged 59%, hurt by a livestreaming crackdown and declining users</li>
<li>The company is pivoting to international markets through its Soulchill and other new apps, targeting overseas revenue growth of up to 100% this year.</li>
</ul>
Hello Group Inc.&nbsp;(MOMO.US) hasn't been too popular on the social scene lately, despite its status as one of China's leading dating app operators.
The owner of Momo, once called the "Tinder of China," has faced years of declining fortunes, which showed no signs of abating in its&nbsp;<a href="https://ir.hellogroup.com/static-files/846c91b2-21ca-4377-944c-67eca869d9ee">latest quarterly report</a>&nbsp;released last week. The results revealed yet another across-the-board slump, with revenue, profitability, and paying memberships all down — extending a decline dating back to 2020, even as the company tries to reposition itself as more than just a hook-up app.
Facing unrelenting domestic pressures — including regulatory scrutiny, market saturation and shifting user behavior to other platforms like short video sensation Douyin — company executives are now ramping up a long-touted overseas strategy in search of relief. While Hello Group has explored international markets since 2020, its leadership last week pledged bolder action on that front, pointing to rapid progress over the past year.
Before taking a closer look at Hello Group's overseas expansion, including its 2024 progress and looming challenges, we'll unpack the company's latest quarterly results to show where it currently stands. Its report underscores that its domestic slump isn't easing, explaining why the company views international markets as its most viable route to jumpstart its business.
Hello Group reported revenue of 2.6 billion yuan ($359 million) for the quarter through December, down 12% year-over-year. This extends a pattern of quarterly contractions dating back to the first quarter of 2020, with only one brief respite in the second quarter of 2023 when it eked out 1% growth. On an annual basis, revenue also fell by 12% in 2024, marking a fifth consecutive year of decline since peaking in 2019.&nbsp;
The company's profitability also deteriorated significantly, with fourth-quarter net income tumbling 59% to 187.2 million yuan from 452.5 million yuan a year earlier. For all of 2024, net income fell by nearly 50% to 1 billion yuan.&nbsp;&nbsp;&nbsp;
<h4 class="wp-block-heading">International expansion</h4>
Hello Group's declining fortunes stem partly from its struggle to keep pace with China's rapidly evolving social media landscape, where users are increasingly flocking to fast-growing new platforms, especially short video sites like Douyin and the popular Xiaohongshu social community site. The changing landscape is posing acute challenges for Hello Group's core business model of facilitating connections between strangers.
The company's struggle to adapt is reflected in the steady user declines across its two major apps, Momo and Tantan. In the fourth quarter, Tantan's monthly active users fell by 2.9 million to 10.8 million. While active user data for the larger Momo app wasn't disclosed, its paying users dropped to 5.7 million from 7.4 million year-over-year. Tantan's paying users similarly declined to 900,000 from 1.2 million. The declines are even more striking when compared to 2021, when Momo and Tantan boasted 9 million and 3 million paying users, respectively.
The company's falling revenue owes in no small part to the exodus of paying users, who primarily subscribe to premium services offering advanced features such as profile boosting. However, the most significant blow remains a regulatory crackdown that has limited gifting to livestreamers since 2020. That's severely affected Hello Group, as it heavily relied on commissions from user gifts to livestreamers.
The impact is evident in the company's revenue composition. In 2017 and 2018, livestreaming services contributed about 80% of Hello Group's revenue. But the amount has steadily declined during the clampdown, and in 2024 livestreaming revenue fell 16% year-over-year to 5.1 billion yuan, accounting for 48% of total revenue. Starting from the third quarter of 2023, value-added services — primarily membership fees — have overtaken livestreaming as the company's largest single revenue source.
This domestic crisis has forced Hello Group to step up its overseas drive, where executives see "clear growth potential" versus a more uncertain domestic market. The strategy centers on Soulchill, a social app targeting Middle Eastern markets. Soulchill's revenue surged 50% year-over-year in 2024 to nearly 1 billion yuan, overtaking Tantan's dwindling contribution. The company attributes the success to localized strategies, including culturally tailored virtual gifts and targeted livestreaming features.
<h4 class="wp-block-heading">Geographic expansion</h4>
According to CFO Peng Hui, the company plans to expand beyond its current markets of Turkey, Egypt, and Persian Gulf countries into developed markets in 2025, though specific targets remain undisclosed.
Hello Group is further expanding its overseas portfolio with two new apps launched in late 2023: Yaahlan, an Arabic-focused audio social game app combining gaming with voice interactions, and AMAR, a voice-based platform targeting young users in the Middle East and North Africa (MENA). According to COO Zhang Sichuan, both apps began monetization in late 2024 and are generating stable returns despite initial marketing costs.
CFO Peng projects overseas revenue will grow from 1 billion yuan in 2024 to between 1.7 billion yuan and 2 billion yuan in 2025. "If (return on investment) remains stable, we could see these newer apps reach Soulchill's current revenue scale by year-end," Peng noted on the company's earnings call. Peng said that profitability remains secondary to scaling efforts for now, meaning the overseas push is likely to keep eroding Hello Group's profits for at least the next year or two.
The expansion strategy also comes with its own risks. The company's heavy Middle East focus suggests a need for rapid diversification, as evidenced by COO Zhang's acknowledgment that instability in the MENA region impacted user spending in late 2024. Hello Group also faces competition in the region from two other social media companies with Chinese backgrounds,&nbsp;Yalla&nbsp;(YALA.US) and&nbsp;Newborn Town&nbsp;(9911.HK).
Marketing costs could also surge as Hello Group enters competitive Western markets, where it will face stiff competition from both established local rivals as well as global players like&nbsp;Match Group&nbsp;(MTCH.US).
Despite these challenges, executives view overseas expansion as crucial. COO Zhang emphasized that the company's "long-standing expertise in social entertainment products" justifies shifting resources to international markets, where it expects better returns than in the stagnant and highly competitive domestic market.
Investors remain skeptical. Hello Group's shares tumbled 8% the day of the earnings release, reflecting concerns about the sustainability of its domestic cash cow service and the capital required for overseas bets. The stock is up 12% over the last six months, but that's well behind the 45% rally for the Hang Seng China Enterprises Index over that time, showing investors are hardly convinced on the company's turnaround strategy.

Tech

MOMO

Hello Group Shares Shrug Off Upbeat 2025 Outlook

Wedbush analyst Matt Bryson reiterates Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Outperform and maintains $125 price target.

Wedbush Reiterates Outperform on Micron Technology, Maintains $125 Price Target

Press Releases

VSee Health Announces $935K Contracts with Major Medical Device Manufacturers

VSee Health Announces $870K Contract with National Mental Health Services Company

VSee Health Secures $340K Contract to Create AI-Enabled EHR System

VSee Health Secures $2M Contract Renewal for Neurocritical Care Expansion at Leading Hospital System

VSee Health Announces Contract with Top Kidney Care Provider to Add VSee Workflow to Oracle Cerner EHR

VSee Health Secures $560K Contract to Deploy Virtual Command Center for Major Oncology Network, Strengthening Growth Trajectory in Digital Health Market

VSee Health and LanguageLine Team Up to Boost Telehealth Adoption with Seamless, Scalable Multilingual Care

VSee Health Secures $444K County Government Contract, Expanding Market Reach in Public Sector Healthcare

VSee Issues Shareholder Letter Highlighting 2024 Achievements and Strong Growth Outlook for 2025

Leader in AI Powered Telehealth Redefining the $787 Billion Digital Healthcare Market with Technology Advancements, New Partnerships and Expanding Client Base: VSee Health (Nasdaq: VSEE)

Comments

VSee Health

Interés en corto

VSee Health (NASDAQ:VSEE) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL